Search research articles
Contact Us
Filters
Showing results (311-320 of 457) with videos related to
Page
of 46
Sort By:
Lymphokine and Cytokine Research
|
June 1, 1992
Variation in serum levels of the soluble TNF receptors among healthy individuals
D Aderka, H Engelmann, Y Shemer-Avni, et al.
Annales De Dermatologie Et De Venereologie
|
January 1, 1985
[Congenital corporal hemihypertrophy with hypertrichosis]
D Wallach, D Jayle, M D Vignon-Pennamen, et al.
The Journal of Biological Chemistry
|
June 10, 1978
Filamin-actin interaction. Dissociation of binding from gelation by Ca2+-activated proteolysis
P J Davies, D Wallach, M C Willingham, et al.
Annales De Dermatologie Et De Venereologie
|
January 1, 1988
[Synovialosarcoma]
M D Vignon-Pennamen, D Wallach, O Verola, et al.
BMC Medicine
|
June 18, 2019
Postmarketing commitments for novel drugs and biologics approved by the US Food and Drug Administration: a cross-sectional analysis
Joshua D Wallach, Anita T Luxkaranayagam, Sanket S Dhruva, et al.
Journal of Reproductive Immunology
|
July 1, 1995
Soluble tumor necrosis factor receptors and soluble interleukin-6 receptor in fetal and maternal sera, coelomic and amniotic fluids in normal and pre-eclamptic pregnancies
S L Opsjøn, D Novick, N C Wathen, et al.
Annales De Dermatologie Et De Venereologie
|
January 1, 1989
[Multiple eruptive keratoacanthoma disclosing lymphoma]
P P Cabotin, M D Vignon-Pennamen, J M Miclea, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
June 1, 1986
M. leprae and PPD-triggered T cell lines in tuberculoid and lepromatous leprosy
P Shankar, F Agis, D Wallach, et al.
JAMA Network Open
|
May 11, 2019
Analysis of Postapproval Clinical Trials of Therapeutics Approved by the US Food and Drug Administration Without Clinical Postmarketing Requirements or Commitments
Joshua J Skydel, Anita T Luxkaranayagam, Sanket S Dhruva, et al.
JAMA Internal Medicine
|
November 23, 2020
Characteristics and Reporting of Number Needed to Treat, Number Needed to Harm, and Absolute Risk Reduction in Controlled Clinical Trials, 2001-2019
Marissa H Elliott, Joshua J Skydel, Sanket S Dhruva, et al.
Page
of 46
Search research articles
Search
Showing results (311-320 of 457) with videos related to
Sort By:
Page
of 46
Lymphokine and Cytokine Research
|
June 1, 1992
Variation in serum levels of the soluble TNF receptors among healthy individuals
D Aderka, H Engelmann, Y Shemer-Avni, et al.
Annales De Dermatologie Et De Venereologie
|
January 1, 1985
[Congenital corporal hemihypertrophy with hypertrichosis]
D Wallach, D Jayle, M D Vignon-Pennamen, et al.
The Journal of Biological Chemistry
|
June 10, 1978
Filamin-actin interaction. Dissociation of binding from gelation by Ca2+-activated proteolysis
P J Davies, D Wallach, M C Willingham, et al.
Annales De Dermatologie Et De Venereologie
|
January 1, 1988
[Synovialosarcoma]
M D Vignon-Pennamen, D Wallach, O Verola, et al.
BMC Medicine
|
June 18, 2019
Postmarketing commitments for novel drugs and biologics approved by the US Food and Drug Administration: a cross-sectional analysis
Joshua D Wallach, Anita T Luxkaranayagam, Sanket S Dhruva, et al.
Journal of Reproductive Immunology
|
July 1, 1995
Soluble tumor necrosis factor receptors and soluble interleukin-6 receptor in fetal and maternal sera, coelomic and amniotic fluids in normal and pre-eclamptic pregnancies
S L Opsjøn, D Novick, N C Wathen, et al.
Annales De Dermatologie Et De Venereologie
|
January 1, 1989
[Multiple eruptive keratoacanthoma disclosing lymphoma]
P P Cabotin, M D Vignon-Pennamen, J M Miclea, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
June 1, 1986
M. leprae and PPD-triggered T cell lines in tuberculoid and lepromatous leprosy
P Shankar, F Agis, D Wallach, et al.
JAMA Network Open
|
May 11, 2019
Analysis of Postapproval Clinical Trials of Therapeutics Approved by the US Food and Drug Administration Without Clinical Postmarketing Requirements or Commitments
Joshua J Skydel, Anita T Luxkaranayagam, Sanket S Dhruva, et al.
JAMA Internal Medicine
|
November 23, 2020
Characteristics and Reporting of Number Needed to Treat, Number Needed to Harm, and Absolute Risk Reduction in Controlled Clinical Trials, 2001-2019
Marissa H Elliott, Joshua J Skydel, Sanket S Dhruva, et al.
Page
of 46